CHAPTER 2: <strong>Health</strong> carehow FDA uncovers <strong>and</strong> communicates importantdrug safety issues. For example, FDA will focus onimproving the safety <strong>of</strong> drugs on the market in partthrough its plans to modernize the Adverse EventReporting System (AERS) <strong>and</strong> establish “AERS II” asthe primary source for drug product adverse eventdata. These resources also will allow FDA to augmentAERS data <strong>and</strong> further its efforts with CMS to obtainaccess to valuable drug safety information housed inCMS population-based databases. This collaborationwith CMS will be integrated with the Sentinel System,a seamless platform for gathering <strong>and</strong> evaluatinginformation about adverse events related to the use <strong>of</strong>medical products. This integration will enable FDA togather more information from the point <strong>of</strong> care aboutpotential safety problems <strong>and</strong> will provide a frameworkfor turning these raw data into useful knowledge aboutthe safe use <strong>of</strong> medical products.In order to improve current processes <strong>and</strong> systemsfor collection <strong>of</strong> adverse events <strong>and</strong> errors, FDA isdeveloping MedWatch Plus. This program will providea single internet portal for anyone needing to reportan adverse event resulting from an FDA regulatedproduct, including product complaint reporting. Thisinitiative will improve the collection <strong>and</strong> processing<strong>of</strong> adverse event information for all FDA regulatedproducts. The user-friendly electronic submissioncapability will facilitate submission <strong>of</strong> adverse eventsreports to better allow FDA to efficiently <strong>and</strong> effectivelyuse the information to promote <strong>and</strong> protect publichealth. Through these modernization efforts, FDAwill continue to ensure that the medical products itregulates are the safest in the world.OPHS coordinates vaccine safety activities amongHHS agencies which conduct a broad range <strong>of</strong>activities aimed at ensuring the safety <strong>of</strong> vaccines.NIH conducts <strong>and</strong> funds basic research that leads tothe development <strong>of</strong> vaccines with a major emphasis onsafety. FDA has statutory responsibility for licensingvaccines. Additionally, the FDA coadministers theVaccine Adverse Event Reporting System (VAERS),a passive surveillance system, with CDC. CDC alsoconducts active surveillance <strong>of</strong> vaccine associatedadverse events through the Brighton Collaboration,<strong>and</strong> examines vaccine adverse events on the practicelevel through Clinical Immunization Safety Assessment(CISA) centers. HRSA compensates individualswho may have been injured by vaccines through theVaccine Injury Compensation Program (VICP). TheFederal government has a heightened responsibilityto ensure that vaccines are optimally safe as vaccinesare recommended for nearly ever child in the U.S. <strong>and</strong>children are required by state laws to receive vaccinesin order to enter school. OPHS is coordinating aninteragency strategic plan to enhance HHS vaccinesafety activities. Vaccine safety activities will beenhanced in the areas <strong>of</strong> research <strong>and</strong> development,post-licensure surveillance, <strong>and</strong> risk communication.Generic Drugs. Part <strong>of</strong> FDA’s mission is to make surethat the generic drugs approved for use in the UnitedStates are just as safe <strong>and</strong> effective as the br<strong>and</strong>-nameversions <strong>of</strong> the drugs. Generic drugs can be very helpfulfor patients because their price is typically much lower:For the average price <strong>of</strong> a br<strong>and</strong>-name prescriptiondrug that is $72, the average price <strong>of</strong> a generic versionis about $17. xiii This is an especially important source<strong>of</strong> drug savings at this time, because a growing number<strong>of</strong> important br<strong>and</strong>-name medications—more than 200in the next few years—are coming <strong>of</strong>f patent, pavingthe way for the development <strong>of</strong> generic versions. FDA’snew final regulation to improve how <strong>and</strong> when genericdrugs can compete with br<strong>and</strong>-name drugs will lead tosaving billions <strong>of</strong> dollars in drug costs each year.<strong>Health</strong> DisparitiesThe Racial <strong>and</strong> Ethnic <strong>Health</strong> Disparities Outreach jointplanning effort focuses on outreach to raise awarenessamong minority communities about major healthrisks prevalent in their specific populations <strong>and</strong> toprovide access to information on how to reduce theserisks. AoA, CDC, IHS, NIH, OCR, <strong>and</strong> OPHS partnerwith media, State <strong>and</strong> local health departments, State<strong>and</strong> area agencies on aging, <strong>and</strong> tribal governments onthis effort. Additional information on HHS’s efforts onthis topic can be found later in this chapter in In theSpotlight: Reducing <strong>Health</strong> Disparities.44 HHS Strategic Plan FY 2007-2012
CHAPTER 2: <strong>Health</strong> careStrategic Objective 1.4Recruit, develop, <strong>and</strong> retain a competenthealth care workforce.In the coming years, the Nation faces shortages <strong>of</strong> criticalhealth care workers, including nurses <strong>and</strong> long-termcare providers. In addition, all health care workerswill need to be flexible <strong>and</strong> responsive enough to acton new challenges <strong>and</strong> maximize the potential <strong>of</strong> newtechnologies. In addition to strategies to develop itsown workforce, HHS is committed to helping the fieldrecruit <strong>and</strong> retain, as well as train, develop, <strong>and</strong> support,a competent pr<strong>of</strong>essional <strong>and</strong> parapr<strong>of</strong>essional healthcare workforce. Among the operating <strong>and</strong> staff divisionscontributing to the achievement <strong>of</strong> this objective areAoA, <strong>ASPE</strong>, CMS, HRSA, IHS, OPHS, <strong>and</strong> SAMHSA.HHS, in the health care programs it operates, faces thesame recruitment <strong>and</strong> retention challenges encounteredby health care providers nationwide. The first performanceindicator measures HHS’s success in meeting its goal torecruit <strong>and</strong> retain the Commissioned Corps membersneeded to provide ongoing health care. The secondmeasures the Corps’ readiness to rapidly respond tomedical emergencies <strong>and</strong> urgent public health needs.Recruitment /Retention EffortsCommissioned Corps. The mission <strong>of</strong> theCommissioned Corps <strong>of</strong> the United States Public <strong>Health</strong>Service (USPHS; Commissioned Corps) is protecting,promoting, <strong>and</strong> advancing the health <strong>and</strong> safety <strong>of</strong>the Nation. The Commissioned Corps achieves itsmission through rapid <strong>and</strong> effective response to publichealth needs, leadership <strong>and</strong> excellence in publichealth practices, <strong>and</strong> the advancement <strong>of</strong> public healthscience. As one <strong>of</strong> the seven Uniformed Services <strong>of</strong> theUnited States, the Commissioned Corps is a specializedcareer system designed to attract, develop, <strong>and</strong> retainhealth pr<strong>of</strong>essionals who may be assigned to Federal,State, or local agencies or international organizations.The Commissioned Corps will continue to <strong>of</strong>fer twoexcellent opportunities for students through the highlycompetitive Junior Commissioned Officer Student Training<strong>and</strong> Extern Program <strong>and</strong> Senior Commissioned OfficerStudent Training <strong>and</strong> Extern Program.HHS Strategic Plan FY 2007-201245